Menu

Lasker Winners Announced

Discoveries related to rapid neurotransmitter release are among those recognized by the Albert and Mary Lasker Foundation this year.

Sep 9, 2013
Tracy Vence

Richard Scheller (left) of Genentech and Thomas Südhof (right) from Stanford University took home the 2013 Albert Lasker Basic Medical Research Award for their work on rapid neurotransmitter release.ALBERT AND MARY LASKER FOUNDATION

Genentech’s Richard Scheller and Thomas Südhof from the Stanford University School of Medicine have won the 2013 Lasker Award for basic medical research. Scheller, executive vice president of research and early development at the South San Francisco-based biotech, and Südhof are being lauded by the Albert and Mary Lasker Foundation for their work unraveling the molecular machinery and regulatory mechanisms behind rapid neurotransmitter release.

In its announcement, the foundation noted that Scheller and Südhof independently identified, isolated, and defined fundamental interactions among the key molecules involved in rapid neurotransmitter release “at a time . . . when not a single protein in the process had been characterized.”

Meantime, the foundation presented its 2013 Lasker Award for clinical research to three scientists who worked to develop the modern cochlear implant, and honored Bill and Melinda Gates for their public service work, “leading a historic transformation in the way we view the globe’s most pressing health concerns and improving the lives of millions of the world's most vulnerable.”

This year’s recipients will each receive a $250,000 honorarium, and will be presented with their awards on Friday, September 20, in New York City. 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.